Stock data
Crescent Biopharma, Inc. (CBIO)
Crescent Biopharma, Inc. (CBIO) reported revenue of US$10.84M and net income of -US$153.94M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | US$10.84M | — | -US$152.63M | -US$153.94M | — |
| 2024 | — | — | -US$40.04M | -US$37.88M | — |
| 2023 | — | — | -US$39.28M | -US$36.90M | — |
| 2022 | — | — | -US$47.40M | -US$46.69M | — |
| 2021 | — | — | -US$63.45M | -US$63.43M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | US$0.00M | -US$24.84M | — |
| 2026-03-31 | US$1.04M | -US$23.28M | — |
| 2025-12-31 | — | -US$23.30M | — |
| 2025-09-30 | — | -US$24.61M | — |
| 2025-06-30 | US$0.00M | -US$21.79M | — |
| 2025-03-31 | US$0.00M | -US$15.15M | — |
| 2024-12-31 | — | -US$7.22M | — |
| 2024-09-30 | — | -US$9.82M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.